Today we’re thrilled to announce the successful completion of our gene therapy collaboration previously announced with Biogen in May 2021!
Together, we aimed to redefine the industry standard for manufacturing recombinant adeno-associated virus (AAV)-based vectors. The collaboration achieved our goals of enhancing the AAV production titers of Biogen’s gene therapy manufacturing processes.
We’re proud to work with industry-defining partners like Biogen to help global leaders in the biopharmaceutical industry redefine what’s possible in therapeutics discovery and manufacturing.
Significant improvements like these are the result of a platform-based approach to biological R&D. They are possible because our program leads work closely with our collaboration partners to take full advantage of the broad scale and deep sophistication of our highly-automated foundry and growing codebase.
Learn more about Ginkgo’s Gene Therapy Services here.
